Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) may be curative for colorectal cancer patients with peritoneal metastases (PMs) but it has a high rate of morbidity. Accurate preoperative patient selection is therefore imperative, but is constrained by the limitations...
Main Authors: | Jamie J. Beagan, Nina R. Sluiter, Sander Bach, Paul P. Eijk, Stijn L. Vlek, Daniëlle A. M. Heideman, Miranda Kusters, D. Michiel Pegtel, Geert Kazemier, Nicole C. T. van Grieken, Bauke Ylstra, Jurriaan B. Tuynman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/6/1738 |
Similar Items
-
Det perioperativa samtalets betydelse för patienter som genomgår peritonektomi och HIPEC : En journalgranskningsstudie
by: Hjelte, Louise, et al.
Published: (2015) -
Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
by: Zhou S, et al.
Published: (2021-03-01) -
Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial
by: M. P. Engbersen, et al.
Published: (2021-04-01) -
P.R.O.P.S. — A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
by: Zachary Zihui Yong, et al.
Published: (2019-08-01) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes
by: Jerzy Mielko, et al.
Published: (2020-08-01)